Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

entities : Bristol-myers squibb company    crawled date : 2021 - 07 - 16    save search

Oncology (Cancer) / Hematologic Malignancies Approval Notifications
Published: 2021-07-16 (Crawled : 19:11) - fda.gov
REGN | $896.27 0.26% 0.25% 500K twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
INCY | $52.3 -0.98% -0.99% 2.2M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
CLVS | $0.0812 -3.94% twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
KPTI | $1.16 -9.38% -10.34% 1.4M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
ADCT | $4.72 -0.84% 0.0% 320K twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
YMAB | $15.15 1.0% 0.99% 470K twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
BPMC | $86.87 -2.28% -2.34% 800K twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
EPZM | $1.47 -1.34% 0.0% twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
BMY | $48.93 1.3% 0.0% 10M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
AVEO | $15.0 0.0% 0 twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
LLY | News | $726.31 -2.63% -0.04% 3.5M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

cancer approval
Bristol Myers Squibb Provides Update on CheckMate -651 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus EXTREME Regimen as First-Line Treatment for Squamous Cell Carcinoma of the Head and Neck
Published: 2021-07-16 (Crawled : 12:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M twitter stocktwits trandingview |
Health Technology
| | O: 0.03% H: 0.0% C: 0.0%

treatment trial cell carcinoma nivolumab
Gainers vs Losers
67% 33%

Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M twitter stocktwits trandingview |
Finance

EGOX | $0.0515 43.06% 30.1% 330M twitter stocktwits trandingview |

OLB 4 | $0.33 -14.95% 25.53% 840K twitter stocktwits trandingview |
Technology Services

NVFY | $2.77 31.28% 23.83% 33M twitter stocktwits trandingview |
Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M twitter stocktwits trandingview |
Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M twitter stocktwits trandingview |
Distribution Services

INSG | $3.03 25.21% 20.13% 330K twitter stocktwits trandingview |
Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K twitter stocktwits trandingview |
Manufacturing

WLGS | $0.59 18.0% 17.9% 2.3M twitter stocktwits trandingview |

ASNS | $0.828 21.75% 17.86% 18K twitter stocktwits trandingview |


Your saved searches
Save your searches and get alerts when important news are released.